DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG: Change in the Management Board of BRAIN AG


 

DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Personnel
B.R.A.I.N. Biotechnology Research And Information Network AG: Change in the Management Board of BRAIN AG

07.05.2020 / 08:00
The issuer is solely responsible for the content of this announcement.


Change in the Management Board of BRAIN AG

Chief Financial Officer Manfred Bender is leaving the biotechnology company at the end of the current financial year. Lukas Linnig to become the new CFO.

Zwingenberg, Germany
07 May 2020

The biotechnology company B.R.A.I.N. Biotechnology Research and Information Network AG announces that Chief Financial Officer Manfred Bender will leave the company at his own request on 30 September 2020. Mr Bender will take on a new assignment and has therefore asked the Supervisory Board to terminate his contract prematurely. The Supervisory Board has complied with this request.

The new Chief Financial Officer will be Lukas Linnig, the current Head of Finance, Controlling and Legal. Linnig has worked for the company since April 2017 and he previously advised BRAIN as a consultant during the IPO.

Dr Georg Kellinghusen, Chairman of the Supervisory Board, says: "We regret Mr Bender's decision, but we respect it. We thank him for his great contribution and commitment to BRAIN AG. With Lukas Linnig, we have found a successor who knows the company extremely well. There is sufficient time for an orderly transition until Mr Bender leaves the company."

Adriaan Moelker, CEO BRAIN AG, commented: "Lukas Linnig has proven that he has all the skills for a strong CFO. I am very pleased to have him on the management board and I am confident that with Lukas' appointment we are taking an important step in building a strong future-orientated team."

About BRAIN

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this "Toolbox of Nature" are successfully applied in the chemistry, the cosmetics and the food industries. BRAIN's business model is based on two pillars. The BioScience segment comprises mainly of the research and development business with industrial partners (the "Tailor-Made Solutions" cooperation business), and the company's own research and development. The BioIndustrial segment consists mainly of the industrially scalable products business. Further information is available at www.brain-biotech.com.

B.R.A.I.N.
Biotechnology Research
And Information Network AG
Darmstädter Str. 34-36
64673 Zwingenberg
Germany
www.brain-biotech.com

Contact Investor Relations
Michael Schneiders
Phone: +49-(0)6251-9331-86
Mobil: +49-(0)172 7957319
Email: [email protected]

Media Contact
Dr. Stephanie Konle
Managing Associate Corporate Communications
Phone: +49-(0)6251-9331-70
Email: [email protected]

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.
 

Follow BRAIN AG on Twitter (Twitter@BRAINbiotech) and LinkedIn (@BRAIN AG)



07.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: B.R.A.I.N. Biotechnology Research And Information Network AG
Darmstädter Straße 34-36
64673 Zwingenberg
Germany
Phone: +49 (0) 62 51 / 9331-0
Fax: +49 (0) 62 51 / 9331-11
E-mail: [email protected]
Internet: www.brain-biotech.com
ISIN: DE0005203947
WKN: 520394
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1037627

 
End of News DGAP News Service

1037627  07.05.2020 

fncls.ssp?fn=show_t_gif&application_id=1037627&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 24,11 27,05 38,56 38,23 38,39 45,51 55,34
EBITDA1,2 -7,70 -6,55 -2,50 -3,88 -2,53 -1,31 -0,83
EBITDA-Marge3 -31,94 -24,21 -6,48 -10,15 -6,59 -2,88
EBIT1,4 -9,37 -9,57 -7,20 -8,23 -6,55 -5,65 -5,48
EBIT-Marge5 -38,86 -35,38 -18,67 -21,53 -17,06 -12,42 -9,90
Jahresüberschuss1 -9,40 -8,37 -11,12 -9,02 -4,68 -6,34 -8,11
Netto-Marge6 -38,99 -30,94 -28,84 -23,59 -12,19 -13,93 -14,66
Cashflow1,7 -5,80 -5,42 -3,38 -4,77 -3,10 -1,49 -4,22
Ergebnis je Aktie8 -0,58 -0,45 -0,61 -0,52 -0,25 -0,30 -0,38
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Baker Tilly

INVESTOR-INFORMATIONEN
©boersengefluester.de
BRAIN Biotech
WKN Kurs in € Einschätzung Börsenwert in Mio. €
520394 3,450 Halten 75,37
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
34,50 0,00 0,00 -7,50
KBV KCV KUV EV/EBITDA
3,46 - 1,36 -121,01
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,00 0,00 0,00 12.03.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
28.02.2024 28.05.2024 29.08.2024 17.01.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-8,15% -14,73% -5,74% -41,53%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu B.R.A.I.N. Biotechnology Research And Information Network AG  ISIN: DE0005203947 können Sie bei EQS abrufen


Biotechnologie , 520394 , BNN , XETR:BNN